RESUMEN
AIMS: Combination of hypertonic saline solution (HSS) with intravenous loop diuretics has been suggested to improve diuretic response in patients hospitalized for heart failure (HF). The efficacy and safety of this approach in the ambulatory setting remain unexplored. METHODS AND RESULTS: In this multicentre, double-blind, randomized study, we allocated ambulatory patients with worsening heart failure (WHF) to a 1-h infusion of intravenous furosemide (ivFurosemide)-HSS versus ivFurosemide. The primary endpoint was the volume of diuresis at 3 h. Secondary endpoints included 3-h natriuresis and weight variation, 7-day congestion data, kidney function and electrolytes, and 30-day clinical events. Overall, 167 participants (median age: 81 years, 30.5% female) were randomized across 13 sites between December 2020 and March 2023. There were no differences in 3-h diuresis between treatments (ivFurosemide-HSS: 1099 ml vs. ivFurosemide: 1103 ml, p = 0.963), 3-h natriuresis (∆ +2.642 mEq/L, p = 0.559), or 3-h weight (∆ +0.012 kg, p = 0.920). Patients in the ivFurosemide-HSS arm experienced significant weight decrease at 7 days (Δ -0.586 kg, p = 0.048). There were no between-treatment differences in clinical congestion score, biomarkers, inferior vena cava diameter, or the presence of lung ultrasound B-lines. At 30 days, 26.5% of the patients in the ivFurosemide-HSS group versus 33.3% in the ivFurosemide group experienced WHF (hazard ratio 0.76, p = 0.330). The incidence of death from any cause or HF hospitalization was 6% of patients in the ivFurosemide-HSS group and 8.3% of patients in the ivFurosemide group (hazard ratio 0.69, p = 0.521). The incidence of worsening kidney function or metabolic derangements was not significantly different in the two arms. CONCLUSIONS: A single infusion of ivFurosemide-HSS did not improve 3-h diuresis or congestion parameters in patients with ambulatory WHF. This therapy showed an appropriate safety profile.
RESUMEN
BACKGROUND: Renin-angiotensin-aldosterone system inhibitors (RAASIs) play a crucial role in the treatment of several chronic cardiovascular conditions. Nonetheless, hyperkalemia, a frequent side effect, often leads to the discontinuation of RAASIs. The implications of hyperkalemia-driven changes in RAASI medications are poorly understood. METHODS: Population-based, observational, retrospective cohort study. Two large healthcare databases were utilized to identify 77,089 individuals aged 55 years and older with chronic conditions who were prescribed RAASIs between 2015 and 2017 in Southern Barcelona, Spain. We assessed the interplay between serum potassium abnormalities, RAASI management, and their associations with clinical outcomes, adjusting for potential confounders including socioeconomic factors, medical conditions, and potassium levels. RESULTS: The one-year prevalence of hyperkalemia (defined as serum potassium, K+ >5.0 mmol/L) was 17.8 %. RAASI were down-titrated in 16.1 % of these 13,673 patients with K+ levels. Factors linked to a higher likelihood of reducing/discontinuing RAASI after developing hyperkalemia included older age, impaired kidney function, higher potassium levels, and previous hospitalizations. Dose reduction/discontinuation of RAASI after developing hyperkalemia was associated with an increased risk of hospitalization (adjusted hazard ratio [HR] 1.16, 95 % confidence interval [CI] 1.10-1.21) and with increased mortality (HR 1.60, 95 % CI 1.56-1.84). CONCLUSION: In this large, observational study, hyperkalemia was linked to a greater likelihood of discontinuing RAASIs. Down-titration of RAASI was independently associated with unfavorable clinical outcomes such as hospitalization and specially mortality. Although the observational nature of the study, these findings underscore the importance of preventing circumstances that may lead to RAASI down-titration, such as hyperkalemia, as well as preventing hospitalizations and mortality, to ensure RAASI benefits.
Asunto(s)
Inhibidores de la Enzima Convertidora de Angiotensina , Enfermedades Cardiovasculares , Hiperpotasemia , Potasio , Sistema Renina-Angiotensina , Humanos , Hiperpotasemia/inducido químicamente , Hiperpotasemia/epidemiología , Femenino , Masculino , Anciano , Estudios Retrospectivos , Persona de Mediana Edad , Inhibidores de la Enzima Convertidora de Angiotensina/efectos adversos , Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Sistema Renina-Angiotensina/efectos de los fármacos , Potasio/sangre , España/epidemiología , Enfermedades Cardiovasculares/epidemiología , Anciano de 80 o más Años , Antagonistas de Receptores de Angiotensina/uso terapéutico , Antagonistas de Receptores de Angiotensina/efectos adversos , Enfermedad Crónica , Hospitalización/estadística & datos numéricosRESUMEN
Cardiovascular disease is a common problem in cancer patients that is becoming more widely recognized. This may be a consequence of prior cardiovascular risk factors but could also be secondary to the anticancer treatments. With the goal of offering a multidisciplinary approach to guaranteeing optimal cancer therapy and the early detection of related cardiac diseases, and in light of the recent ESC Cardio-Oncology Guideline recommendations, we developed a Cardio-Oncology unit devoted to the prevention and management of these specific complications. This document brings together important aspects to consider for the development and organization of a Cardio-Oncology program through our own experience and the current evidence.
RESUMEN
Introducción y objetivos Las alteraciones de la potasemia son frecuentes en las enfermedades cardiovasculares crónicas. El objetivo del estudio es evaluar las asociaciones de la hiperpotasemia y la hipopotasemia con eventos clínicos y costes sanitarios en pacientes con insuficiencia cardiaca, enfermedad renal crónica, diabetes mellitus, hipertensión y cardiopatía isquémica. Métodos Estudio longitudinal que incluyó a 36.269 pacientes de un Área de Salud que tuvieran al menos una de las afecciones mencionadas. Se utilizaron bases de datos administrativas, hospitalarias y de atención primaria. Se siguió a los participantes entre 2015 y 2017; estos tenían 55 o más años y al menos 1 medición de potasio. Se utilizaron 4 diseños analíticos para evaluar la prevalencia y la incidencia y el uso de inhibidores del sistema renina-angiotensina-aldosterona. Resultados La hiperpotasemia fue 2 veces más frecuente que la hipopotasemia. En los análisis ajustados, la hiperpotasemia se asoció de manera significativa con un mayor riesgo de muerte por todas las causas (HR de los modelos de regresión de Cox entre 1,31 y 1,68) y con un aumento de las probabilidades de que los gastos anuales de atención sanitaria superen el 85% (OR entre 1,21 y 1,29). Las asociaciones fueron aún mayores en los pacientes hipopotasémicos (HR para la muerte por todas las causas, 1,92-2,60; OR para los gastos de atención sanitaria> percentil 85, 1,81-1,85). Conclusiones Se necesitarían estudios experimentales para confirmar si la prevención de los trastornos del potasio reduce la mortalidad y los gastos sanitarios en estas enfermedades crónicas. Hasta entonces, nuestros hallazgos proporcionan conclusiones observacionales sobre la importancia de mantener normales las concentraciones de potasio. (AU)
Introduction and objectives Potassium derangements are frequent among patients with chronic cardiovascular conditions. Studies on the associations between potassium derangements and clinical outcomes have yielded mixed findings, and the implications for health care expenditure are unknown. We assessed the population-based associations between hyperkalemia, hypokalemia and clinical outcomes and health care costs, in patients with chronic heart failure, chronic kidney disease, diabetes mellitus, hypertension, and ischemic heart disease. Methods Population-based, longitudinal study including up to 36 269 patients from a health care area with at least one of the above-mentioned conditions. We used administrative, hospital and primary care databases. Participants were followed up between 2015 and 2017, were aged ≥ 55 years and had at least 1 potassium measurement. Four analytic designs were used to evaluate prevalent and incident cases and the use of renin-angiotensin-aldosterone system inhibitors. Results Hyperkalemia was twice as frequent as hypokalemia. On multivariable-adjusted analyses, hyperkalemia was robustly and significantly associated with an increased risk of all-cause death (HR from Cox regression models ranging from 1.311.68) and with an increased odds of a yearly health care expenditure >85th percentile (OR, 1.211.29). Associations were even stronger in hypokalemic patients (HR for all-cause death, 1.922.60; OR for health care expenditure> percentile 85th, 1.811.85). Conclusions Experimental studies are needed to confirm whether the prevention of potassium derangements reduces mortality and health care expenditure in these chronic conditions. Until then, our findings provide observational evidence on the potential importance of maintaining normal potassium levels. (AU)
Asunto(s)
Humanos , Masculino , Femenino , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Insuficiencia Cardíaca , Insuficiencia Renal Crónica , Enfermedad Crónica , Hiperpotasemia , Hipopotasemia , Diabetes Mellitus , Hipertensión , Isquemia Miocárdica , Costos de la Atención en SaludRESUMEN
No disponible
Asunto(s)
Humanos , Disfunción Ventricular/clasificación , Cardiopatías/diagnóstico , Electrocardiografía/métodos , Diagnóstico DiferencialRESUMEN
No disponible